Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.50 |
| ▸ | CA1 known ✓ | P00915 | 16/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 16/20 | 0.41 |
| ▸ | CA4 known ✓ | P22748 | 6/20 | 0.41 |
| ▸ | CA12 known ✓ | O43570 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | EYA2 | O00167 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL9193928 | 0.95 | KDM4E (0.50) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL6284520 | 0.93 | TDP1 (0.50) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL167680 | 0.89 | TDP1 (0.64) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL8371874 | 0.87 | TDP1 (0.61) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL6347093 | 0.84 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL5697081 | 0.84 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL887881 | 0.84 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL59899 | 0.84 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL7870390 | 0.84 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E | |
| Edetic Acid SCHEMBL5305791 | 0.84 | TDP1 (0.70) | TDP1EYA2APPACEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293508-A1 | ANTI-INFECTIVE METHODS, COMPOSITIONS, AND DEVICES | JPMORGAN CHASE BANK, N.A. | 2023-09-21 | — | — | US | claimed |
| US-11654139-B2 | Anti-infective methods, compositions, and devices | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-05-23 | — | — | US | claimed |
| US-20210023069-A1 | ANTI-INFECTIVE METHODS, COMPOSITIONS, AND DEVICES | JPMORGAN CHASE BANK, N.A. | 2021-01-28 | — | — | US | claimed |
| US-10828293-B2 | Anti-infective methods, compositions, and devices | DOW PHARMACEUTICAL SCIENCES, INC. (US) | 2020-11-10 | — | — | US | claimed |
| US-20190209543-A1 | ANTI-INFECTIVE METHODS, COMPOSITIONS, AND DEVICES | JPMORGAN CHASE BANK, N.A. | 2019-07-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209543-A1 | ANTI-INFECTIVE METHODS, COMPOSITIONS, AND DEVICES | ETF1, POLR1C, PIK3C3 | ACE 662/4885CA1 1733/4885CA2 1162/4885 |
| US-11654139-B2 | Anti-infective methods, compositions, and devices | ETF1, POLR1C, PIK3C3 | ACE 662/4885CA1 1733/4885CA2 1162/4885 |
| US-10828293-B2 | Anti-infective methods, compositions, and devices | ETF1, POLR1C, PIK3C3 | ACE 662/4885CA1 1733/4885CA2 1162/4885 |
| US-20230293508-A1 | ANTI-INFECTIVE METHODS, COMPOSITIONS, AND DEVICES | ETF1, POLR1C, PIK3C3 | ACE 662/4885CA1 1733/4885CA2 1162/4885 |
| US-20210023069-A1 | ANTI-INFECTIVE METHODS, COMPOSITIONS, AND DEVICES | ETF1, POLR1C, PIK3C3 | ACE 662/4885CA1 1733/4885CA2 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.